echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The “first-in-class” therapy introduced by Zai Lab for USD 175 million is applied for clinical application!

    The “first-in-class” therapy introduced by Zai Lab for USD 175 million is applied for clinical application!

    • Last Update: 2021-08-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to the latest announcement from the Center for Drug Evaluation (CDE) of the State Drug Administration of China, Zai Lab has submitted three clinical trial applications for efgartigimod injection, which were accepted by the CDE



    In January 2021, Zai Lab and argenx reached an exclusive license cooperation, obtained the exclusive development and commercialization rights of efgartigimod in Greater China, and will be responsible for the global registration clinical research and development of multiple indications of the candidate drug in China



    According to a press release issued by argenx in May 2020, data from the ADAPT study showed that 67.


    The acceptance of the clinical trial application of Efgartigimod injection by CDE means that the drug is expected to start clinical trials in China soon


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.